Cambridge Major Laboratories (CML) today announced a significant expansion of its large-scale Active Pharmaceutical Ingredient (API) manufacturing facility in Germantown.
The expansion comes three years after the company commissioned the state-of-the-art facility.
CML is a leading global chemistry outsourcing partner to the pharmaceutical and biotechnology industries. The company’s global headquarters are in Germantown, where it employs 140 people. The firm also has a plant in The Netherlands, where it employs 60 people.
CML spokeswoman Rebecca Bishop told BizTimes that the $13 million expansion in Germantown will add to the plant’s capacity and workforce.
“We are very pleased to report that our faith in the ‘invest in the West’ policy initiated a few years ago continues to bear fruit,” said Brian Scanlan, president and chief executive officer of the company. “CML is very well positioned to support both increasing demand for our commercial products as well as our healthy pipeline of API’s in later phases of clinical development. By making these new investments, we show our commitment to support our loyal client base at the most critical point, when quality and timely delivery are imperative.”
The expansion will include significant additional reactor capacity as well as isolation equipment. Alongside capacity additions, CML has made additional investments in engineering controls to ensure the sustainability of the business.
“Our environmental, health, and safety commitments underpin all operations, and we have invested further containment capabilities with engineering controls across production trains. Additional containment capabilities will also be introduced into our European facility later this year,” Scanlan said.
